M. Alexander Otto

Circulating tumor DNA (ctDNA) can help predict the risk of relapse in certain cases of early, high-risk breast cancer, according to study presented at the American Society of Clinical Oncology annual meeting.

A new study finds that hormone receptor positivity does not offer a strong positive prognostic advantage for young women with BRCA-associated breast cancer.

Immunotherapy has largely replaced chemotherapy as the last resort in patients at the end of life, but it's not always the right move.

Can patients with rectal cancer who have a near-complete clinical response to total neoadjuvant therapy be watched and potentially spared a permanent ostomy?

In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, experts remain cautiously optimistic.

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or no PD-L1 expressors doesn't outweigh the risks.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

Patients with this rare end-stage cancer complication achieved a median overall survival of nearly a year with proton craniospinal irradiation.

The oral small molecule is the first drug approved for a major driver of acute leukemia in infants.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.